Search Results
Your search for ,aGe matches 8736 pages
Showing 51 - 100Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age
Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen (PSA) screening is low in younger men—but rises sharply with age. The study, which aimed to estimate the impact of age on overdiagnosis of prostate cancer 15 years after screening stops, analyzed...
Tracking Biological Age Changes Gives Insights Into Cancer Prognosis
Face aging rate, a measure of changes in biological age over time, could serve as a noninvasive prognostic biomarker for determining outcomes in patients with cancer, according to the results of a study published in Nature Communications. “Deriving a Face Aging Rate from multiple, routine facial...
Do Political Beliefs Shape Views on Clinical Trials in Cancer?
In a cross-sectional study published in JAMA Network Open, political ideology was associated with clinical trial skepticism, with conservative identification linked to higher odds of endorsing such views. Among cancer survivors, Chido-Amajuoyi et al similarly observed greater skepticism among...
Educational Disparities in Young-Onset Colorectal Cancer Mortality
Rising colorectal cancer death rates among young adults are largely concentrated among those with lower educational attainment, according to a nationwide cross-sectional analysis published in JAMA Oncology. As a result, Jemal et al reported that the disparity in mortality between individuals with...
ACP Issues Controversial New Breast Cancer Screening Guidelines
New guidance from the American College of Physicians (ACP) says all average-risk females between ages 50 to 74 should receive biennial screening mammography for breast cancer, and that females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the...
GLP-1 RAs May Reduce Mortality In Some Patients With Colorectal Cancer and Comorbid Obesity: Real-World Outcomes
Colon cancer is among the leading causes of cancer-related morbidity and mortality worldwide, with alarming increases in incidence and mortality among younger adults. Although the exact causes of these increases are unknown, lifestyle, including poor diets, sedentary habits, smoking, and alcohol...
Long-Term Immunotherapy for Alveolar Soft Part Sarcoma
Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard 2 years, according to results from a phase II clinical trial presented at the American...
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested...
Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions
Injecting the PD-1 inhibitor nivolumab directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial (ClinicalTrials.gov identifier NCT05327270) presented at the American Association for Cancer ...
Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival
As reported in JAMA Oncology by Richardson et al, a secondary analysis of the GAP70+ trial showed that treatment modifications and outcomes did not differ between older patients with advanced cancer who prioritized quality of life (QOL) vs those who preferred prolonging survival. Study Details This ...
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
Patients with advanced platinum-resistant ovarian cancer who had experienced disease progression on standard therapy exhibited clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial (ClinicalTrials.gov...
Melanoma: Can AI Enable Diagnosis Prediction?
Assessment of machine-learning models tested on Swedish registry data enabled more accurate melanoma diagnosis prediction, with added health-care code, age, sex, and medication information for improved performance, according to the results of a study published in Acta Dermato-Venereologica. “Our...
AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms
About one in six survivors of an adolescent and young adult cancer will develop a subsequent primary neoplasm within 30 years of their original diagnosis, according to the results of a population-based study published in the Canadian Medical Association Journal. “When combined with the relatively...
LuPSMA-617 and Pembrolizumab in mCRPC
In an Australian phase IB to II study (PRINCE) reported in The Lancet Oncology, Sandhu et al found that the combination of lutetium-177–labeled PSMA-617 (LuPSMA-617) and pembrolizumab showed “encouraging” activity in patients with metastatic castration-resistant prostate cancer (mCRPC). As stated ...
Is Standard of Care Optimal for the Individual Patient?
I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded his facial nerve. Several weeks ago, when the PA’s fingers moved over the mass visibly protruding...
Global Survival Index for Childhood Cancer: CONCORD-4
As reported in The Lancet, Allemani et al identified findings in the CONCORD-4 study indicating the degree of progress towards the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) target of 60% 5-year survival for all childhood cancers combined by the year 2030. Study...
Can Saying ‘I Do’ Reduce Cancer Risk?
A U.S. population-based study across demographic groups and cancer types found that ever-married adults consistently had a lower cancer risk compared with never-married individuals. Published in Cancer Research Communications, these findings suggest that marital status may serve as a valuable...
POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy
For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or longer in high-risk patients, is both a...
Analysis of Constitutional Cancer Predisposition Gene Variants in Nearly 15,000 Patients
In a UK retrospective cohort study reported in The Lancet Oncology, Whitworth et al analyzed the frequency of germline genetic variants in patients with cancer in the 100,000 Genomes Project. Study Details The study included data from 14,765 individuals with cancer entered into the 100,000 Genomes...
CLL Linked to Increased Skin Cancer Risk and Mortality
In a nationwide population–based cohort study reported in JAMA Dermatology, Blomberg Drejøe et al evaluated the long-term risk of skin cancer and related outcomes among patients with chronic lymphocytic leukemia (CLL). By leveraging comprehensive Danish health registries, the investigators aimed to ...
Researchers Identify Blood-Based Biomarker for Cancer Risk in People With Lynch Syndrome
Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help identify and characterize asymptomatic people with Lynch syndrome who are more susceptible to developing cancer based on early immune detection signatures, allowing clinicians...
How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs
As the data continue to show, the incidence of breast, testis, and other cancers are on the rise in adolescent and young adults (AYAs) between the ages of 15 and 39, with increases of 30% over the last 4 decades.1 And while potential explanations for this rapid increase have included obesity,...
Damaging Missense Variants in Innate Immunity Genes Linked to Earlier Breast Cancer Onset in BRCA1 Carriers
Damaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast cancer onset in carriers of the BRCA1 genetic mutation, according to preliminary findings published by Shemesh et al in the Journal of Medical Genetics. The strongest...
NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
The National Comprehensive Cancer Network® (NCCN®) brought together more than a thousand oncology professionals at the NCCN 2026 Annual Conference in Orlando, with hundreds more joining virtually. This year’s event featured educational sessions on breakthroughs in cancer prevention and treatment,...
Surgery Still Safe, Beneficial For Many Octogenarian Patients With NSCLC
Surgical treatment was found to be safe and demonstrate long-term quality-of-life benefits for carefully selected octogenarians with early-stage non–small cell lung cancer (NSCLC), according to findings from a prospective cohort study published in The Lancet Regional Health: Americas. “As our...
Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the...
FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL
The U.S. Food and Drug Administration (FDA) has granted traditional approval to the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The full approval now includes efficacy, safety, and...
Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment
Many people with lung cancer can be treated with a highly precise, high dose of radiation given in just one session without compromising the effectiveness of the treatment. The treatment strategy, outlined in a new publication authored by Singh et al in the International Journal of Radiation...
Presence of ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence
Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer may predict whether they are likely to experience relapse—especially when samples are taken after the patients have received treatments prior to surgery. Findings presented at the 15th European Breast Cancer...
Low-Risk Endometrial Cancer: Does a Lack of Adjuvant Therapy Affect Survival?
In a study reported in a research letter in JAMA Oncology, Matsuo et al found that survival without adjuvant therapy in women with low-risk endometrial cancer was poorer among those with isolated tumor cells (ITCs) vs no lymph node metastasis in regional lymph nodes. Study Details The cohort...
Financial Hardship and Late-Stage Cancer Diagnosis
In a study reported in the Journal of Clinical Oncology, Khor et al found that prediagnosis financial hardship was associated with a diagnosis of cancer at later stages, particularly for cancers with organized screening programs and those detectable via physical examination. Study Details The...
Agent Orange Exposure Linked to MDS Risk and Progression
In a recent study published in Blood Advances, Sekeres et al examined whether exposure to Agent Orange, a dioxin-contaminated herbicide used during the Vietnam War, is associated with the development and clinical characteristics of myelodysplastic syndromes (MDS). Given the established links...
One-Time Low-Dose CT Screening May Reduce Lung Cancer Mortality Among Neversmokers in Asia
One-time low-dose computed tomography (CT) screening for lung cancer in a non–risk-based Chinese population led to a significant reduction in lung cancer mortality, according to the results of a prospective, nonrandomized, controlled study presented at the European Lung Cancer Congress 2026...
Risk of Subsequent Cancer in Solid Organ Transplant Recipients With Pretransplant Cancer History
In a study reported in JAMA Oncology, Tao et al found that U.S. solid organ transplant (SOT) recipients with a history of pretransplant cancer were at increased risk of subsequent cancer. Study Details The cohort study used linked data from the U.S. Scientific Registry of Transplant Recipients and ...
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy, or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989, given as monotherapy or in combination with...
Breast Reconstruction Using Polyurethane-Coated Implants May Reduce the Risk of Capsular Contracture, Additional Surgery
Women who are treated with mastectomy for breast cancer often choose to have breast reconstructive surgery using an implant. But hard, painful scar tissue can form around the implant, especially when women also receive radiotherapy as part of their treatment. Findings from the OPBC-09 PRExRT study, ...
Using AI to Differentiate Primary Lung Squamous Cell Carcinomas From Metastases
A multipronged artificial intelligence (AI)–assisted approach integrated into routine molecular profiling identified 3.1% of cases submitted as lung squamous cell carcinoma as metastases from other origins, revealing a meaningful rate of misdiagnosis in this patient population, according to a...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
In Celebration of a Decades-Long Journey of Discovery and Innovation
On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds the titles of Director of Dana-Farber/Harvard Cancer Center, the Richard and Susan Smith Professor of ...
SIOG 2025: Celebrating 25 Years of Leadership in Geriatric Oncology
The 25th Annual Conference of the International Society of Geriatric Oncology (SIOG) convened in Ghent, Belgium, from November 20 to 22, 2025, marking a quarter-century of international collaboration dedicated to improving cancer care for older adults. Held under the theme “Bridging Research and...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
Among patients with acute myeloid leukemia (AML) who were treated with intensive chemotherapy on clinical trials from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), Black race was found to be an independent predictor of inferior survival, with outcomes not being explained by cytogenetic risk....
Three AI-Enabled Analyses Highlight Context-Dependent Biomarkers in Early-Onset Colorectal Cancer
Biomarker discovery in colorectal cancer has traditionally focused on identifying molecular alterations with broad prognostic or predictive utility. However, evidence is increasingly suggesting that biomarkers do not have universal prognostic or predictive value across patient sets but instead...
The Thymus Plays a Part in Adult Cancer Risk and Treatment Response, Research Reveals
Two papers published in Nature reveal long-disregarded functions of the thymus in adulthood, showing that the overall health of the organ impacts aging and risks for cardiovascular disease and cancer, as well as affecting response to immunotherapy in patients with cancer. “The thymus has been...
Does Metformin Use Reduce the Risk of Esophageal Cancer?
Metformin use was linked to lower odds of developing esophageal squamous cell carcinoma in a Nordic population–based case-control study, according to findings published by Xie et al in JAMA Network Open. “This should prompt investigations of metformin as a preventive option in high-risk individuals ...
Study Finds No Overall Increase in Cancer Risk After Medically Assisted Reproduction
Overall cancer incidence is similar between women who have used medically assisted reproduction and the general population, but certain cancers may occur at slightly higher rates, according to an Australian population–based cohort study published in JAMA Network Open by Vajdic et al. The...
For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels before treatment. In the study, reported at the 2026 ASCO Genitourinary Cancers Symposium,1 men with...
SMFM Issues New Clinical Guidance for Cancer Diagnosis and Treatment During Pregnancy
As the incidence of cancer among reproductive-age people continues to increase in the United States—with approximately one out of every 1,000 pregnancies complicated by cancer—the Society for Maternal-Fetal Medicine (SMFM) has issued its first evidence-based clinical guidance for diagnosing and...
Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
A new analysis suggests that prostate cancer screening may compare favorably with screening for breast cancer in terms of identifying significant cancers, reducing mortality, and avoiding unnecessary harms, according to findings presented at the 2026 Annual Congress of the European Association of...
Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria
One in 10 patients who present to the emergency department with visible hematuria may die within 3 months, new research from the United Kingdom has indicated. The WASHOUT study, presented at the European Association of Urology Congress (EAU26) in London, found that a scan administered within 48...
